Out-Licensed Compounds/Programs
| Compound | Principal Target | Partner | Stage of Development |
|---|---|---|---|
XL880 |
VEGFR2, MET |
GlaxoSmithKline |
Phase 2
|
XL147 |
PI3K |
Sanofi-Aventis |
Phase 2
|
XL765 |
PI3K, mTOR |
Sanofi-Aventis |
Phase 1b/2
|
XL518 |
MEK |
Genentech/Roche |
Phase 1b
|
XL652/XL041 |
LXR |
Bristol-Myers Squibb |
Phase 1
|
XL139 |
Hedgehog |
Bristol-Myers Squibb |
Phase 1
|
XL281 |
RAF |
Bristol-Myers Squibb |
Phase 1
|
XL475 |
TGR5 |
Bristol-Myers Squibb |
Preclinical
|
XL550 |
MR |
Daiichi-Sankyo |
Phase 1
|
Isoform Selective PI3Kα and PI3Kβ |
PI3Kα and PI3Kβ |
Sanofi-Aventis |
Preclinical
|
ROR Antagonists |
ROR antagonists |
Bristol-Myers Squibb |
Preclinical
|